CAMBRIDGE, Mass., April 28, 2025--Ankyra Therapeutics, a leading clinical-stage company developing anchored drug conjugates for the treatment of cancer, today presented preliminary data ...

The Phase 1 study (NCT05635643) is a dose escalation, dose optimization and expansion study evaluating CHS-114 as a monotherapy and in combination with toripalimab, a next generation PD-1 inhibitor.

Demonstrated strong safety and favorable pharmacokinetics in Phase 1 study A First-in-class oral small molecule modulating immune cell metabolism via glycogen phosphorylase inhibition Once-daily ...

Findings from the Phase 1 dose escalation portion of the EXACT trial of XC001 in refractory angina provided the dose selection and safety justification for the recently completed Phase 1/2 study ...

“I am particularly excited with the analysis of the results of our Phase 1 trial, as it marks the successful achievement of another critical milestone for SAB-142,” stated Samuel J ...